Literature DB >> 10898704

In vitro activity and fecal concentration of rifaximin after oral administration.

Z D Jiang1, S Ke, E Palazzini, L Riopel, H Dupont.   

Abstract

Rifaximin showed moderately high MICs (the MIC at which 90% of the isolates tested were inhibited = 50 microg/ml) for 145 bacterial enteropathogens from patients with traveler's diarrhea acquired in Mexico during the summers of 1997 and 1998. Rifaximin concentrations in stool the day after oral administration (800 mg daily for 3 days) were high (average, 7,961 microg/g), proving the value of the drug.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10898704      PMCID： PMC90042          DOI： 10.1128/AAC.44.8.2205-2206.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Ferrieri; A Venturi; C Brignola; M Ferretti; S Peruzzo; M Miglioli; M Campieri
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

2.  Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

Authors:  F Miglio; D Valpiani; S R Rossellini; A Ferrieri
Journal:  Curr Med Res Opin       Date:  1997       Impact factor: 2.580

3.  Rifaximin systemic absorption in patients with ulcerative colitis.

Authors:  F Rizzello; P Gionchetti; A Venturi; M Ferretti; S Peruzzo; X Raspanti; M Picard; N Canova; E Palazzini; M Campieri
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

4.  Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin.

Authors:  G R Corazza; M Ventrucci; A Strocchi; M Sorge; L Pranzo; R Pezzilli; G Gasbarrini
Journal:  J Int Med Res       Date:  1988 Jul-Aug       Impact factor: 1.671

5.  Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy.

Authors:  S Verardi; V Verardi
Journal:  Farmaco       Date:  1990-01

6.  Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

Authors:  W W Hoover; E H Gerlach; D J Hoban; G M Eliopoulos; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1993-02       Impact factor: 2.803

7.  Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

Authors:  J J Descombe; D Dubourg; M Picard; E Palazzini
Journal:  Int J Clin Pharmacol Res       Date:  1994

8.  Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone.

Authors:  H L DuPont; R R Reves; E Galindo; P S Sullivan; L V Wood; J G Mendiola
Journal:  N Engl J Med       Date:  1982-09-30       Impact factor: 91.245

9.  High-level quinolone resistance in clinical isolates of Campylobacter jejuni.

Authors:  J Segreti; T D Gootz; L J Goodman; G W Parkhurst; J P Quinn; B A Martin; G M Trenholme
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

Review 10.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546
View more
  43 in total

1.  In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea.

Authors:  J M Sierra; J Ruiz; M M Navia; M Vargas; J Vila
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

Review 3.  Rifamycins, Alone and in Combination.

Authors:  David M Rothstein
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

4.  Management of Clostridium difficile Infection.

Authors:  Layth S Al-Jashaami; Herbert L DuPont
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-10

5.  Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Authors:  Farah Babakhani; Jaime Seddon; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

Authors:  S M Finegold; D Molitoris; M-L Väisänen
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 7.  Rifaximin: a review of its use in the management of traveller's diarrhoea.

Authors:  Gayle W Robins; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

Authors:  Scott R Curry; Jane W Marsh; Kathleen A Shutt; Carlene A Muto; Mary M O'Leary; Melissa I Saul; A William Pasculle; Lee H Harrison
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

Review 9.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

10.  The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Authors:  Hoonmo L Koo; Herbert L Dupont; David B Huang
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.